What does CUSIP 92859E108 represent in this 13F holders report?

CUSIP 92859E108 is the security identifier for VVOS - VIVOS THERAPEUTICS INC - COM used to aggregate holder disclosures.

How many institutions held VVOS - VIVOS THERAPEUTICS INC - COM in Q1 2022?

23 institutional investors reported VVOS - VIVOS THERAPEUTICS INC - COM for Q1 2022. Use the holders table for investor-level position and value details.

VIVOS THERAPEUTICS INC - COM (VVOS)

CUSIP: 92859E108

Q1 2022 13F Holders as of 31 Mar 2022

Security type / class: Equity / COM
Total 13F shares: 2,483,693
Total 13F value: $6,651,020
Share change: +251,634
Put/Call ratio: 129%
SEC-reported price per share: $2.68
Number of holders: 23
Value change: +$809,146
Number of buys: 16
Number of sells: 12

Security key

92859E108

Report period

Q1 2022

Institutions

Top holders

VVOS full security history Ownership snapshot Full 13F holder table Vivos Therapeutics, Inc. SEC filings Vivos Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VVOS - VIVOS THERAPEUTICS INC - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Gurdev Dave Singh

Disclosed value leader

Gurdev Dave Singh

Comparable rows

0/15

Latest evidence

31 Dec 2021

3/4/5 13F Highest disclosed value: $1,728,844 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Gurdev Dave Singh has the largest disclosed position value at $1.73M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Gurdev Dave Singh's linked filing trail.

Disclosed position value Top 5

Gurdev Dave Singh $1.73M

VANGUARD GROUP INC $1.49M

Russell Investments Group, Ltd. $684K

BARD ASSOCIATES INC $480K

PERKINS CAPITAL MANAGEMENT INC $306K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Gurdev Dave Singh	3/4/5 Chief Medical Officer, Director, 10%+ Owner 3/4/5	— mixed-class rows	$1,728,844 3,266,372 shares mixed-class rows	—	05 Aug 2021
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$1,492,000 663,253 shares	—	31 Dec 2021
Russell Investments Group, Ltd.	13F Company 13F	— denominator unverified	$684,000 305,096 shares	—	31 Dec 2021
BARD ASSOCIATES INC	13F Company 13F	— denominator unverified	$480,000 213,502 shares	—	31 Dec 2021
PERKINS CAPITAL MANAGEMENT INC	13F Company 13F	— denominator unverified	$306,000 136,050 shares	—	31 Dec 2021
Anson Funds Management LP	13F Company 13F	— denominator unverified	$275,000 122,297 shares	—	31 Dec 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

2,483,693

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Holder diff

Investor	Q1 2022 Shares	Q1 2022 Shares	Share Diff	Share Chg %	Q1 2022 value	Q1 2022 value	Value change	Value Chg %